PTSD market expected to reach $5.5bn across the 7MM by 2034
A major focus of research and development (R&D) in the PTSD therapeutic space is the development of new therapeutic options with improved efficacy. As no medications have been approved by the US Food and Drug Administration (FDA) for the treatment of PTSD since 2001, antidepressants of the selective-serotonin reuptake inhibitors (SSRIs) class, of which Zoloft and Paxil are the only approved drugs for PTSD, have been relied upon by physicians worldwide and the consensus is that this strategy is unsuitable for many patients. While SSRIs can result in symptom reduction for PTSD patients, less than 30% of patients achieve remission. The PTSD pipeline is diverse with novel mechanisms of action that developers hope can provide greater efficacy than the SSRIs.
One significant area of research is into psychedelic therapeutics. Key opinion leaders (KOLs) interviewed by GlobalData consistently highlighted midomafetamine hydrochloride (MDMA) as the most promising psychedelic therapeutic for PTSD, with Lykos Therapeutics' MDMA-assisted psychotherapy expected to achieve blockbuster status by the end of the forecast period. Despite a challenging path towards the market, having been initially rejected by the FDA in August 2024 and KOLs noting some concerns surrounding trial design and company practice, as the first psychedelic to reach the market for PTSD, GlobalData forecasts Lykos' drug will generate $1.1 billion in sales across the 7MM by 2034.
Despite their promise, many regulatory challenges exist for psychedelic therapeutics, particularly those that are being developed in conjunction with psychotherapy, including how to attribute benefits between the drug component and the psychotherapy component in a trial, especially as the FDA does not regulate psychotherapy. Furthermore, the known effects of psychedelics make double-blind placebo control, the gold standard for clinical trials, difficult to achieve, as patients can identify when they have received the active compound. This leads to concerns of expectation bias in participants, which can affect the evaluation of the true efficacy of a drug. The other psychedelic therapeutics in the late-stage PTSD pipeline are Compass Pathways' psilocybin and Seelos Therapeutics' ketamine.
In addition to the three psychedelic therapeutics, there are five non-psychedelic pipeline products in the late-stage PTSD pipeline that GlobalData expects to launch during the forecast period (2024-2034). These are Otsuka's Rexulti, which is currently in preregistration in the US, Neuphoria Therapeutics' BNC-210, Idorsia Pharmaceuticals' Quviviq, Ananda Scientific's Nantheia ATL5, and Transcend Therapeutics' TSND-20. Many of these products have safety profiles favourable to the current treatment options, helping to meet another key unmet need in the PTSD market as the problem of side effects with existing treatments leads to low patient compliance rates. GlobalData expects that the five non-psychedelic pipeline products will generate $2.3bn in sales in the 7MM by 2034.
"PTSD market expected to reach $5.5bn across the 7MM by 2034" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
35 minutes ago
- USA Today
Wegmans chocolate sold in 8 states recalled over undeclared allergen
A Wegmans chocolate product was recently recalled due to the presence of an undeclared allergen. Mellace Family Brands California, Inc. of Warren, Ohio initiated the recall, informing the Food and Drug Administration on June 25 that Wegmans Semi-Sweet Chocolate Nonpareils, chocolate-flavored balls made of sugar and starch, contained milk. "The recall was initiated after it was discovered that Wegmans Semi-Sweet Chocolate Nonpareils contained a milk allergen and was distributed in packaging that did not reveal the presence of milk," the FDA notice says. "(A) subsequent investigation indicates the problem was caused by a temporary breakdown in the suppliers' manufacturing process." Anyone with an allergy or severe sensitivity to milk run the risk of a serious or life-threatening allergic reaction if they consume the recalled product, according to the FDA notice. The candy was distributed through Wegmans stores in eight states, including Delaware, Maryland, Massachusetts, North Carolina, New Jersey, New York, Pennsylvania, Virginia and Washington D.C. There have been no confirmed reports of injuries or illness due to the consumption of the chocolate-flavored decorative confections. Here's what to know about the Wegmans chocolate recall. Need a break? Play the USA TODAY Daily Crossword Puzzle Wegmans chocolate recall: Affected products Consumers who have purchased the Wegmans Semi-Sweet Chocolate Nonpareils with specific lot codes are urged to return the product to the place of purchase for a full refund. According to the FDA notice, the product is packaged in a plastic tub labeled Wegmans Semi-Sweet Chocolate Nonpareils 18.5oz (1LB 2.5OZ) 524g, UPC 0 77890 49787 6, SCC 10077890497873. The product's lot code and best by date can be found on the left side of the tub. Affected lot codes include: Consumers with any questions, or concerns about the recalled product may contact Wegmans Food Markets by phone at (855)-934-3663 from 8 a.m. through 8 p.m. ET daily.
Health Line
an hour ago
- Health Line
Does Medicare Cover Methoxsalen?
Medicare may cover methoxsalen capsules (Oxsoralen-Ultra) when used with UV light therapy for treating psoriasis. Plus, Medicare may cover the injection form of methoxsalen (Uvadex) when prescribed for treating cutaneous T-cell lymphoma (CTCL) that hasn't responded to other treatments as part of a special kind of light therapy called photopheresis. Medicare coverage for methoxsalen capsule Medicare Part D and Medicare Advantage Prescription Drug (MAPD) plans may cover methoxsalen as part of light therapy for psoriasis if other treatments haven't worked for the condition and your doctor has clearly documented this for Medicare. That said, whether your plan covers the brand name or the generic drug depends on your specific plan. In addition, while methoxsalen with light therapy may be effective for treating other skin issues like vitiligo, Medicare usually covers medications based on the conditions approved by the Food and Drug Administration (FDA). Medicare coverage for methoxsalen injection Medicare may also cover the injection form of this medication when combined with photopheresis to help treat CTCL if other treatments haven't worked and a doctor has also documented this for Medicare. But in this case, doctors don't inject the drug directly into your body. Instead, they inject it into the instrument during the photopheresis process. Because of this, if your treatment is covered, the injection drug will likely fall under the coverage of Medicare Part B. The procedure itself is usually covered by Part B as long as it's done in a clinic and doesn't require a hospital stay. If you need to receive it while you're in the hospital, though, it might then be covered under Part A.
Health Line
2 hours ago
- Health Line
What's the Connection Between Statins and Dementia?
There are conflicting research findings as to whether the use of statins can protect from dementia or increase the risk of dementia. While some older research has pointed to the possibility of a correlation, more recent studies showed that this drug class may lower your risk for dementia, including Alzheimer's disease. Statins are a type of medication taken to lower cholesterol levels in the blood. They prevent an enzyme called hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), which is involved in the production of cholesterol in the liver. Benefits of statins Benefits include lowering LDL ('bad') cholesterol levels, reducing the risk of heart disease, and preventing plaque buildup in your arteries. These medications include atorvastatin (Lipitor) and rosuvastatin (Crestor), among others. In 2012, the Food and Drug Administration issued a warning that statin use could rarely cause memory loss or confusion. The FDA later updated the findings that this cognitive decline was not significant. A growing body of research suggests statins may have a protective effect against dementia. A review of 31 studies published in 2018 supports the idea that statins can help prevent the risk of dementia. The researchers found that taking statins for 1 year decreased dementia risk by about 20%, while an average daily 5-milligram (mg) dose was associated with an 11% decrease in dementia risk. The researchers noted that because high cholesterol is a risk factor for dementia, lowering it could have positive effects on the brain. According to a 2020 review, statins may help short- and long-term delay of dementia progression in people over 65 years old with the condition, although the researchers noted that their findings were insufficient to make a definitive statement. Studies in 2021 and 2023 also pointed in the direction of statins having a protective effect against dementia, though the results were not conclusive. Research discrepancies Researchers in a 2022 study pointed out that discrepancies among studies is possibly related to smaller sample sizes and biases in the research methods, as well as wide ranges in the ages of participants, and co-existing conditions. Additionally, these researchers pointed out that different types of statins have different cognitive effects. Most scientists and medical professionals agree that more research is needed on the cognitive effects of statins, and there are studies in progress. If you have high cholesterol, it's important to get advice from a medical professional. High cholesterol is a risk factor for diseases that can affect your independence and life span, such as: heart disease dementia stroke heart attack While some people can experience improvement with lifestyle modifications, many who have high cholesterol need to take cholesterol-lowering medication. You and your doctor can discuss a plan that's individualized for you.
